Skip to main content

IAVI B002

Phase:
I
Status:
Completed
Strategies:
Protein; Viral Vector - Adeno
Candidates:
Adjuvanted GSK investigational HIV vaccine formulation 1; Adjuvanted GSK investigational HIV vaccine formulation 2; Ad35-GRIN
Countries:
Kenya;Uganda;Zambia
Volunteers:
147
Partners:
Kenya AIDS Vaccine Initiative-Kenyatta National Hospital (KAVI-KNH), Nairobi, Kenya; Uganda Virus Research Institute-International AIDS Vaccine Initiative (UVRI-IAVI), Entebbe, Uganda; Medical Research Council (MRC)-Masaka, Uganda; Zambia-Emory HIV Research Project (ZEHRP)-Lusaka, Zambia; GlaxoSmithKline.

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of an adjuvanted investigational HIV vaccine developed by GlaxoSmithKline and Ad35-GRIN in 4 different regimens at months 1, 2, 3, and 4.